SuperGen announces withdrawal of Orathecin marketing authorization application from the European Medicines Agency (SUPG) 5.05 : SUPG withdraws its marketing authorization application for Orathecin capsules, its investigational drug being developed for the treatment of pancreatic cancer in patients who have failed at least one prior chemotherapy regimen, from the European Medicines Agency (E.M.E.A). Co says its decision is based on extensive discussions with the E.M.E.A. SUPG has a Phase II clinical trial ongoing in the U.S. studying Orathecin and gemcitabine as a first-line combination therapy for advanced pancreatic cancer patients who have not undergone chemotherapy. Co plans to make a decision on future development or the alternative disposition of Orathecin based on a review of the interim results of this trial, expected to occur during 1H '06.
Caspermick
"TOUGH TIMES NEVER LAST BUT TOUGH PEOPLE DO."
God Bless America
In Gambling,,,Playing Card Games. Ya Never Know What The Next Hand Will Look Like.
Ten Bagger Potential Stock
